Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome

Branch, D Ware; Elliott, C Gregory; Evans, R Scott; Lloyd, James F; Rondina, Matthew T; Stevens, Scott M; Gallo, Heather M; Wilson, Emily L.; Aston, Valerie T; Woller, Scott C.; Johnson, Eric G.; Kaplan, David A.

doi:10.1177/1076029615615960

Record: found
Abstract: not found
Article: not found

Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome : Study Rationale and Design (ASTRO-APS)

Author(s): Scott C. Woller , Scott M. Stevens , David A. Kaplan , D. Ware Branch , Valerie T. Aston , Emily L. Wilson , Heather M. Gallo , Eric G. Johnson , Matthew T. Rondina , James F. Lloyd , R. Scott Evans , C. Gregory Elliott

Publication date Created: August 31 2015

Publication date (Print): November 12 2015

Journal: Clinical and Applied Thrombosis/Hemostasis

Publisher: SAGE Publications

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Antiphospholipid syndrome (APS) is an acquired thrombophilia characterized by thrombosis, pregnancy morbidity, and the presence of characteristic antibodies. Current therapy for patients having APS with a history of thrombosis necessitates anticoagulation with the vitamin K antagonist warfarin, a challenging drug to manage. Apixaban, approved for the treatment and prevention of venous thrombosis with a low rate of bleeding observed, has never been studied among patients with APS.

Related collections

Most cited references 18

Record: found
Abstract: not found
Article: not found

Guidelines on the investigation and management of antiphospholipid syndrome.

David Keeling, Ian Mackie, Gary W Moore … (2012)

0 comments Cited 119 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies

G Ruiz-Irastorza, MJ Cuadrado, I Ruiz-Arruza … (2011)

The antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or pregnancy morbidity in combination with the persistent presence of circulating antiphospholipid antibodies: lupus anticoagulant, anticardiolipin antibodies and/or anti-β2-glycoprotein I antibodies in medium to high titers. The management of thrombosis in patients with APS is a subject of controversy. This set of recommendations is the result of an effort to produce guidelines for therapy within a group of specialist physicians in Cardiology, Neurology, Hematology, Rheumatology and Internal Medicine, with a clinical and research focus on APS.